About Kimia Biosciences Limited
Data last updated:
Kimia Biosciences Limited is a public limited company based in Gurgaon, Haryana, India, a subsidiary of Kimia Biosciences Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 27 September 1993 and has been in existence for over 33 years.
The company is registered with the Registrar of Companies (ROC), Haryana, under CIN L24239HR1993PLC032120. Its GSTIN is 06AAACL2068E1ZV (Haryana). The company holds 8 GST registrations, of which 3 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 530313.
The company has an authorised share capital of ₹16.39 Cr and a paid-up capital of ₹12.73 Cr. It was formerly known as Laurel Organics Limited and Dolphin Organics Limited. It is led by directors including Sameer Goel (Managing Director) and Jagdeep Dhawan.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Gurgaon, Haryana.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹114.88 Cr, a decline of 3.4% compared to the previous year. For the same year it recorded a net profit of ₹7.42 Cr (net margin 6.5%) and EBITDA of ₹14.26 Cr (EBITDA margin 12.4%). The net worth stands at ₹17.72 Cr (up 77.9% YoY). Total assets are valued at ₹53.94 Cr (up 4.2% YoY).
The company has about 229 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹32.11 Cr and satisfied charges of ₹111.62 Cr on record. Court records list 7 cases involving the company, including 6 filed by the company and 1 filed against it; 2 cases are pending.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website kimiabiosciences.com.
Company details
Name history
Kimia Biosciences has undergone 2 name changes throughout its history. The company was previously known as Laurel Organics Limited, and Dolphin Organics Limited. The current legal name is Kimia Biosciences Limited.
| Company Name | Status |
|---|---|
| Kimia Biosciences Limited | Current |
| Laurel Organics Limited | Previous |
| Dolphin Organics Limited | Previous |
Contact details
Kimia Biosciences Limited's registered office is in Gurgaon, Haryana. Its website is kimiabiosciences.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressVillage Bhondsi, Tehsil Sohna, Gurgaon, Haryana, India – 122102
- IndustryPharma, API Manufacturers, Pharma Contract R&D
To see the full contact details of Kimia Biosciences Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Kimia Biosciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Kimia Biosciences Limited, buy the company report.
Financials of Kimia Biosciences Limited
FY 2025-26 filings availableKimia Biosciences Limited reported revenue of ₹114.88 Cr (down 3.4% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 115 | 119 | 105 | 129 | 125 | 133 | 106 |
| Revenue growth | -3.4% | +13.4% | -18.4% | +2.9% | -5.9% | +24.9% | - |
| EBITDA | 14.26 | 20.24 | (0.48) | (6.02) | 0.64 | 8.37 | 4.46 |
| EBITDA margin | +12.4% | +17.0% | -0.5% | -4.7% | +0.5% | +6.3% | +4.2% |
| Profit before tax | 8.45 | 13.62 | (7.18) | (12.39) | (5.01) | 5.53 | 1.23 |
| Net profit | 7.42 | 9.60 | (5.30) | (8.30) | (3.77) | 5.03 | 1.40 |
| Net profit margin | +6.5% | +8.1% | -5.1% | -6.5% | -3.0% | +3.8% | +1.3% |
| EPS (₹) | 1.57 | 2.03 | (1.12) | (1.98) | (0.78) | 1.08 | 0.30 |
| Balance sheet | |||||||
| Total assets | 53.94 | 51.77 | 52.64 | 67.00 | 63.86 | 71.87 | 56.64 |
| Net worth | 17.72 | 9.96 | 0.33 | 5.46 | 14.89 | 18.44 | 13.37 |
| Total debt | 34.79 | 33.03 | 43.71 | 52.92 | 40.61 | 44.93 | 33.92 |
| Cash & bank | 0.82 | 0.68 | 0.53 | 0.50 | 0.52 | 1.67 | 0.77 |
| Net working capital | 14.36 | 15.84 | 14.07 | 28.36 | 27.38 | 37.43 | 31.51 |
| Cash flow | |||||||
| Cash from operations | 10.84 | 21.31 | 14.53 | (6.77) | 8.00 | 5.97 | 0.31 |
| Cash from investing | (8.09) | (4.70) | (1.49) | (2.80) | (0.71) | (13.60) | (8.63) |
| Cash from financing | (2.64) | (16.55) | (13.07) | 9.54 | (7.67) | 7.99 | 8.46 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.72 | 27.20 | 30.10 | 34.00 | 23.58 | 38.24 | 30.10 | 28.18 |
| Revenue growth (YoY) | -12.1% | -28.9% | 0.0% | +20.7% | +5.3% | - | - | - |
| Other income | 0.08 | 1.01 | 0.10 | (0.33) | 0.85 | 0.44 | 0.42 | 0.37 |
| Total expenses | 18.38 | 24.53 | 23.55 | 31.48 | 21.06 | 30.06 | 25.10 | 24.81 |
| EBITDA | 2.34 | 2.67 | 6.55 | 2.52 | 2.52 | 8.18 | 5.00 | 3.37 |
| EBITDA margin | +11.3% | +9.8% | +21.8% | +7.4% | +10.7% | +21.4% | +16.6% | +12.0% |
| Depreciation | 1.11 | 1.16 | 0.85 | 0.97 | 0.94 | 0.88 | 0.82 | 0.79 |
| Interest | 0.83 | 0.75 | 0.75 | 0.27 | 1.75 | 1.40 | 1.01 | 1.04 |
| Profit before tax | 0.48 | 1.77 | 5.05 | 0.95 | 0.68 | 6.34 | 3.59 | 1.91 |
| Tax | 0.13 | 1.39 | (0.39) | (0.07) | 0.09 | 4.35 | (0.98) | 0.30 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.72 | 27.20 | 30.10 | 34.00 | 23.58 | 38.24 | 30.10 | 28.18 |
| Revenue growth (YoY) | -12.1% | -28.9% | 0.0% | +20.7% | +5.3% | - | - | - |
| Other income | 0.08 | 1.01 | 0.10 | (0.33) | 0.85 | 0.44 | 0.42 | 0.37 |
| Total expenses | 18.38 | 24.53 | 23.55 | 31.48 | 21.06 | 30.06 | 25.10 | 24.81 |
| EBITDA | 2.34 | 2.67 | 6.55 | 2.52 | 2.52 | 8.18 | 5.00 | 3.37 |
| EBITDA margin | +11.3% | +9.8% | +21.8% | +7.4% | +10.7% | +21.4% | +16.6% | +12.0% |
| Depreciation | 1.11 | 1.16 | 0.85 | 0.97 | 0.94 | 0.88 | 0.82 | 0.79 |
| Interest | 0.83 | 0.75 | 0.75 | 0.27 | 1.75 | 1.40 | 1.01 | 1.04 |
| Profit before tax | 0.48 | 1.77 | 5.05 | 0.95 | 0.68 | 6.34 | 3.59 | 1.91 |
| Tax | 0.13 | 1.39 | (0.39) | (0.07) | 0.09 | 4.35 | (0.98) | 0.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 115 | 119 | 105 | 129 | 125 | 133 | 106 |
| Revenue growth | -3.4% | +13.4% | -18.4% | +2.9% | -5.9% | +24.9% | - |
| Other income | 1.62 | 1.32 | 1.64 | 1.21 | 0.93 | 2.46 | 0.96 |
| Total expenses | 101 | 98.68 | 105 | 135 | 124 | 124 | 102 |
| Employee cost | 12.62 | 13.68 | 15.15 | 16.40 | 15.08 | 14.09 | 10.80 |
| EBITDA | 14.26 | 20.24 | (0.48) | (6.02) | 0.64 | 8.37 | 4.46 |
| EBITDA margin | +12.4% | +17.0% | -0.5% | -4.7% | +0.5% | +6.3% | +4.2% |
| Depreciation | 3.91 | 3.38 | 3.29 | 3.33 | 2.94 | 1.91 | 1.66 |
| Interest | 3.52 | 4.56 | 5.05 | 4.25 | 3.64 | 3.39 | 2.53 |
| Profit before tax | 8.45 | 13.62 | (7.18) | (12.39) | (5.01) | 5.53 | 1.23 |
| Tax | 1.03 | 4.02 | (1.88) | (3.04) | (1.32) | 0.43 | (0.16) |
| Net profit | 7.42 | 9.60 | (5.30) | (8.30) | (3.77) | 5.03 | 1.40 |
| Net profit margin | +6.5% | +8.1% | -5.1% | -6.5% | -3.0% | +3.8% | +1.3% |
| EPS (₹) | 1.57 | 2.03 | (1.12) | (1.98) | (0.78) | 1.08 | 0.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 4.73 | 4.73 | 4.73 | 4.73 | 4.73 | 4.73 | 4.73 |
| Reserves & surplus | 12.99 | 5.23 | (4.40) | 0.73 | 10.16 | 13.71 | 8.64 |
| Shareholders' funds (net worth) | 17.72 | 9.96 | 0.33 | 5.46 | 14.89 | 18.44 | 13.37 |
| Secured loans | 24.04 | 22.77 | 24.23 | 28.53 | 20.06 | 26.33 | 16.15 |
| Unsecured loans | 10.75 | 10.26 | 19.48 | 24.39 | 20.55 | 18.60 | 17.77 |
| Total debt | 34.79 | 33.03 | 43.71 | 52.92 | 40.61 | 44.93 | 33.92 |
| Total liabilities | 53.94 | 51.77 | 52.64 | 67.00 | 63.86 | 71.87 | 56.64 |
| Assets | |||||||
| Gross block | 59.85 | 52.24 | 47.43 | 45.93 | 44.19 | 34.45 | 22.32 |
| Net block | 37.33 | 33.28 | 31.84 | 33.63 | 35.23 | 28.37 | 17.85 |
| Capital work in progress | 0.17 | 0.00 | 0.58 | 0.61 | 0.00 | 5.77 | 5.74 |
| Investments | 0.00 | 0.00 | 0.00 | 0.06 | 0.06 | 0.06 | 0.42 |
| Inventories | 26.26 | 34.58 | 30.80 | 48.23 | 37.02 | 23.69 | 20.31 |
| Sundry debtors | 29.32 | 36.75 | 27.55 | 30.59 | 30.20 | 41.77 | 37.33 |
| Cash & bank balances | 0.82 | 0.68 | 0.53 | 0.50 | 0.52 | 1.67 | 0.77 |
| Loans & advances | 7.22 | 3.28 | 2.52 | 3.36 | 5.27 | 4.66 | 2.12 |
| Total current assets | 63.62 | 75.29 | 61.40 | 82.68 | 73.01 | 71.79 | 60.53 |
| Total current liabilities | 49.26 | 59.45 | 47.33 | 54.32 | 45.63 | 34.36 | 29.02 |
| Net working capital | 14.36 | 15.84 | 14.07 | 28.36 | 27.38 | 37.43 | 31.51 |
| Total assets | 53.94 | 51.77 | 52.64 | 67.00 | 63.86 | 71.87 | 56.64 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.21 | 0.15 | 0.18 | 0.20 | 0.59 | 0.23 | 0.09 |
| Net cash from operating activities | 10.84 | 21.31 | 14.53 | (6.77) | 8.00 | 5.97 | 0.31 |
| Net cash from investing activities | (8.09) | (4.70) | (1.49) | (2.80) | (0.71) | (13.60) | (8.63) |
| Net cash from financing activities | (2.64) | (16.55) | (13.07) | 9.54 | (7.67) | 7.99 | 8.46 |
| Net change in cash | 0.11 | 0.06 | (0.03) | (0.03) | (0.38) | 0.35 | 0.14 |
| Closing cash | 0.82 | 0.68 | 0.53 | 0.50 | 0.52 | 1.67 | 0.77 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -3.4% | +13.4% | -18.4% | +2.9% | -5.9% | +24.9% | - |
| EBITDA growth | -29.6% | +4316.7% | +92.0% | -1040.6% | -92.4% | +87.7% | - |
| PBT growth | -38.0% | +9998.0% | +42.1% | -147.3% | - | +349.6% | -67.6% |
| Net income growth | -22.7% | +281.1% | +36.1% | -120.2% | -175.0% | +259.3% | - |
| Revenue CAGR (3Y) | -3.7% | -1.6% | -7.6% | +6.5% | +10.0% | +20.2% | +317.6% |
| EBITDA CAGR (3Y) | - | +216.2% | - | - | -51.4% | +50.2% | - |
| Profitability & leverage | |||||||
| Net income margin | +6.5% | +8.1% | -5.1% | -7.3% | -3.0% | +3.8% | +1.3% |
| Return on capital employed | +22.5% | +34.6% | 0.0% | 0.0% | -2.0% | +13.9% | +7.7% |
| Return on net worth | +52.1% | +172.5% | 0.0% | 0.0% | -22.2% | +32.2% | +14.7% |
| Debt / equity | 2.45 | 7.46 | 16.69 | 4.60 | 2.57 | 2.48 | 3.31 |
| Long-term debt / equity | 1.21 | 3.13 | 9.06 | 2.72 | 1.58 | 1.65 | 2.48 |
| Interest cover | 34.01 | 27.05 | -133.95 | -45.45 | -158.26 | 52.48 | 90.36 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.05 | 2.39 | 2.25 | 2.85 | 3.18 | 4.68 | 5.13 |
| Inventory turnover | 3.78 | 3.64 | 2.65 | 3.02 | 4.11 | 6.03 | 5.84 |
| Debtors turnover | 3.48 | 3.70 | 3.61 | 4.23 | 3.47 | 3.36 | 3.20 |
| EPS (₹) | 1.57 | 2.03 | (1.12) | (1.98) | (0.78) | 1.08 | 0.30 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 3.75 | 2.11 | 0.07 | 1.15 | 3.15 | 3.90 | 2.86 |
To see the full year-wise statements and ratios of Kimia Biosciences Limited, buy the company report.
Board of directors and KMP of Kimia Biosciences Limited
Kimia Biosciences Limited currently reports 4 directors and 1 key managerial person. 22 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jagdeep Dhawan | Director | 29 Mar 2016 | 10 Years 7 Months | Current |
| Sameer Goel Also directs: Magnizent Biochem LLP, Biotavia Pharm Private Limited, Zeneses Biosciences Private Limited and 3 more | Managing Director | 29 Mar 2016 | 10 Years 7 Months | Current |
| Richa Gupta | Director | 15 Apr 2016 | 10 Years 6 Months | Current |
| Naveen Sharma | Cfo | 10 Jan 2026 | 0 Years 9 Months | Current |
| Vijaya Sekhar Reddy Kaku Also directs: Hydex Chemicals Private Limited | Additional Director | 29 Dec 2025 | 0 Years 10 Months | Current |
Peer comparison
Kimia Biosciences Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers, Biosciences, Contract Research), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Nuray Chemicals Private Limited | ₹122.27 Cr (FY 2025) | 16.0% | Thiruvallur, Tamil Nadu, India | |||
| Glenfin Chemicals Private Limited | ₹121.15 Cr (FY 2023) | 21.0% | Thane, Maharashtra, India | |||
| Vivimed Labs Limited | ₹120.64 Cr (FY 2025) | -24.0% | Karnataka, India | |||
| Anlon Healthcare Limited | ₹120.46 Cr (FY 2025) | 81.0% | Rajkot, Gujarat, India | |||
| Galaxy Laboratories Private Limited | ₹120.18 Cr (FY 2025) | 17.0% | Aurangabad, Maharashtra, India | |||
| Vartika Chemicals & Pharmaceuticals Private Limited | ₹120.07 Cr (FY 2025) | -17.0% | New Delhi, Delhi, India | |||
| Virchow Chemicals Pvt. Ltd. | ₹120.01 Cr (FY 2020) | -26.0% | Hyderabad, Telangana, India | |||
| Surya Life Sciences Limited | ₹118.61 Cr (FY 2025) | 12.0% | Navi Mumbai, Maharashtra, India | |||
| Kimia Biosciences Limitedthis company | ₹114.88 Cr (FY 2026) | ₹7.42 Cr | 6.5% | -3.4% | 229 | Gurgaon, Haryana, India |
To see the full peer comparison of Kimia Biosciences Limited, buy the company report.
Auditor
Kimia Biosciences Limited is audited by Singhi & Co. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Singhi & Co. | FY 2023 | 302049E |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 74.90%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.40% and retail and other public shareholders hold 24.70%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 74.90% | 74.90% | 74.90% | 74.90% |
| Public | 25.10% | 25.10% | 25.10% | 25.10% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 10 Apr 2026 | 101269703 | Others | ₹29.6 Cr | Open | |
| 29 Mar 2025 | 101101682 | Others | ₹1.25 Cr | Open | |
| 17 Aug 2022 | 100659188 | Hdfc Bank Limited | ₹96 Lakh | Open | |
| 24 Mar 2022 | 100572936 | Hdfc Bank Limited | ₹21 Lakh | Open | |
| 06 Jun 2020 | 100459261 | Hdfc Bank Limited | ₹9.1 Lakh | Open |
To see the full charge records of Kimia Biosciences Limited, buy the company report.
Total charge records: 18 View all charges
Legal cases
Kimia Biosciences Limited has 7 court cases on record: 6 filed by Kimia Biosciences, 1 filed against it. 2 cases are pending and 5 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 1 | 2 |
| High courts | 2 | 0 | 0 |
| Supreme Court | 2 | 0 | 0 |
Cases on record (5 of 7)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Gurugram, Haryana | Civil suit | Filed against the company by individuals | Pending |
| District court, North West, Delhi | Criminal case | Filed by the company against individuals | Pending |
| District court, North West, Delhi | Criminal case | Filed by the company against an individual | Disposed |
| Supreme Court | Court case (9999-Other) | Filed by the company against State of Haryana . | Disposed |
| High Court, CHANDIGARH (UT) | Court case (RA-CW) | Filed by the company against State of Haryana and Ors | Disposed |
To see the full case history of Kimia Biosciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Kimia Biosciences Limited has 12 MSME Form 1 returns on record between 2019 and 2023, listing 203 overdue payments to 10 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 10)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Beetal Financial and Computer Services Private Limited | |||
| an individual supplier | |||
| an individual supplier | |||
| Quantum Drugs & Chemicals | |||
| High Class Projects Limited |
To see the full MSME payment records of Kimia Biosciences Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Kimia Biosciences Limited has a workforce of 229 employees on its EPFO records as of Apr 07, 2024, across 1 active EPFO establishment.
GST
Kimia Biosciences has 8 GST registrations: 3 active and 5 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 06AAACL2068E1ZV | Haryana | Active | 01 Jul 2017 |
| 06AAACL2068E2ZU | Haryana | Active | 15 Apr 2025 |
| 36AAACL2068E1ZS | Telangana | Active | 06 Feb 2024 |
To see the full GST registrations and return filing status of Kimia Biosciences Limited, buy the company report.
Recent activity
Kimia Biosciences Limited has 33 board changes on record since 2000: 19 appointments and 14 cessations. The latest: Naveen Sharma was appointed as CFO on 10 Jan 2026.
58 earlier events are in the company report.
News
Frequently asked questions
Kimia Biosciences is an active public limited company based in Gurgaon, Haryana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 27 September 1993 (33+ years old) and is registered under CIN L24239HR1993PLC032120. Listed on BSE: 530313.
Kimia Biosciences reported revenue of ₹114.88 Cr for FY 2025-26 (down 3.4% YoY) based on standalone financials.
Kimia Biosciences has 5 current directors and KMP:
- Sameer Goel - Managing Director
- Jagdeep Dhawan - Director
- Richa Gupta - Director
- Vijaya Sekhar Reddy Kaku - Additional Director
- Naveen Sharma - Cfo
The latest financial statements of Kimia Biosciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Kimia Biosciences is 06AAACL2068E1ZV, registered in Haryana. The company has 8 GST registrations in all, of which 3 are active and 5 are cancelled or inactive. Other active GSTINs include 06AAACL2068E2ZU (Haryana), 36AAACL2068E1ZS (Telangana).
The CIN (Corporate Identification Number) of Kimia Biosciences is L24239HR1993PLC032120. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Kimia Biosciences is a listed company as per MCA records. Its shares are listed on BSE (code: 530313).
Kimia Biosciences has 7 court cases on record: 6 filed by the company and 1 filed against it. 2 are pending. Most are in the district courts.
Kimia Biosciences was incorporated on 27 September 1993, making it 33+ years old. It is registered with the Registrar of Companies, Haryana.
The peers of Kimia Biosciences by revenue are Nuray Chemicals Private Limited, Glenfin Chemicals Private Limited, Vivimed Labs Limited, Anlon Healthcare Limited, Galaxy Laboratories Private Limited and 3 more, all in the Pharma industry (API Manufacturers, Biosciences, Contract Research), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Naveen Sharma was appointed as CFO on 10 Jan 2026. Vipul Goel ceased to be Director on 31 Dec 2025. Vijaya Sekhar Reddy Kaku was appointed as Additional Director on 29 Dec 2025. Kimia Biosciences has 33 board changes on record in total.
Kimia Biosciences has 12 MSME Form 1 returns on record between 2019 and 2023, listing 203 overdue payments to 10 micro and small suppliers. The latest return was filed on 27 Aug 2023.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
